Exagen Inc (XGN)

Currency in USD
9.140
+0.150(+1.67%)
Real-time Data·
XGN Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
Trading near 52-week High
XGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.8359.210
52 wk Range
2.3809.210
Key Statistics
Prev. Close
8.99
Open
9
Day's Range
8.835-9.21
52 wk Range
2.38-9.21
Volume
150.73K
Average Volume (3m)
328.66K
1-Year Change
266.94%
Book Value / Share
0.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.167
Upside
+22.17%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price movements are quite volatile

Exagen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Exagen Inc Company Profile

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient’s blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Exagen Inc SWOT Analysis


Diagnostic Dominance
Exagen's AVISE CTD test drives impressive revenue growth, with Q1 2024 showing a 28% year-over-year increase and improved gross margins approaching 60%
Strategic Expansion
Explore Exagen's plans to introduce new rheumatoid arthritis markers in Q4 2024, potentially enhancing diagnostic capabilities and market position
Financial Trajectory
Analysts project positive outlook with price targets ranging from $5 to $7, reflecting confidence in Exagen's growth potential and market opportunities
Navigating Challenges
Learn how Exagen addresses flat test volumes and competitive pressures while leveraging its strong cash position of $76.4 million to fuel growth initiatives
Read full SWOT analysis

Exagen Inc Earnings Call Summary for Q2/2025

  • Exagen reported record Q2 2025 revenue of $17.2M, up 14% YoY, beating forecasts but missed EPS with $0.21 loss
  • Stock surged over 10% post-earnings; analysts maintain strong buy consensus with $7-$12 price targets
  • Gross margin improved to 60.3%; company expanded product offerings and sales territories
  • Full-year revenue guidance of $65-70M; positive adjusted EBITDA expected by Q4 2025
  • CEO highlights growth strategy in autoimmune diagnostics; aims for sustainable profitability in 2026
Last Updated: 29/07/2025, 15:06
Read Full Transcript

Compare XGN to Peers and Sector

Metrics to compare
XGN
Peers
Sector
Relationship
P/E Ratio
−11.8x−1.0x−0.5x
PEG Ratio
−1.46−0.050.00
Price/Book
9.5x2.2x2.6x
Price / LTM Sales
3.4x9.2x3.3x
Upside (Analyst Target)
22.4%316.2%43.4%
Fair Value Upside
Unlock10.3%7.1%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.167
(+22.17% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
-0.21 / -0.15
Revenue / Forecast
17.20M / 16.23M
EPS Revisions
Last 90 days

XGN Income Statement

People Also Watch

248.86
AVAV
-4.14%
6.995
TRON
-1.76%
158.93
CRCL
+3.92%
9.940
TDUP
+0.40%
61.620
CDTX
-0.18%

FAQ

What Stock Exchange Does Exagen Trade On?

Exagen is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Exagen?

The stock symbol for Exagen is "XGN."

What Is the Exagen Market Cap?

As of today, Exagen market cap is 201.11M.

What Is Exagen's Earnings Per Share (TTM)?

The Exagen EPS (TTM) is -0.89.

When Is the Next Exagen Earnings Date?

Exagen will release its next earnings report on 17 Nov 2025.

From a Technical Analysis Perspective, Is XGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Exagen Stock Split?

Exagen has split 0 times.

How Many Employees Does Exagen Have?

Exagen has 212 employees.

What is the current trading status of Exagen (XGN)?

As of 08 Aug 2025, Exagen (XGN) is trading at a price of 9.14, with a previous close of 8.99. The stock has fluctuated within a day range of 8.84 to 9.21, while its 52-week range spans from 2.38 to 9.21.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.